Daniel M. Witt, PharmD, FCCP, BCPS
Witt DM. Review: Rivaroxaban causes less fatal bleeding, but does not reduce mortality, compared with VKAs. Ann Intern Med. 2013;159:JC13. doi: 10.7326/0003-4819-159-6-201309170-02013
Download citation file:
Published: Ann Intern Med. 2013;159(6):JC13.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Venous Thromboembolism.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only